Two Sigma Investments LP bought a new position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 211,204 shares of the company's stock, valued at approximately $378,000. Two Sigma Investments LP owned approximately 0.48% of ESSA Pharma as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the business. Two Sigma Securities LLC acquired a new stake in shares of ESSA Pharma during the fourth quarter valued at about $29,000. Cubist Systematic Strategies LLC purchased a new stake in ESSA Pharma in the fourth quarter valued at approximately $47,000. Lepercq Multi Asset Fund acquired a new position in ESSA Pharma during the fourth quarter worth $54,000. XTX Topco Ltd purchased a new position in shares of ESSA Pharma during the fourth quarter worth $67,000. Finally, Jane Street Group LLC purchased a new position in shares of ESSA Pharma during the fourth quarter worth $82,000. 75.12% of the stock is currently owned by institutional investors and hedge funds.
ESSA Pharma Price Performance
Shares of EPIX stock traded down $0.03 during trading on Friday, reaching $1.67. The company's stock had a trading volume of 39,103 shares, compared to its average volume of 340,367. ESSA Pharma Inc. has a 1-year low of $1.40 and a 1-year high of $7.88. The stock's 50-day moving average price is $1.70 and its 200 day moving average price is $1.69. The company has a market capitalization of $74.13 million, a price-to-earnings ratio of -2.42 and a beta of 1.58.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, sell-side analysts anticipate that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
About ESSA Pharma
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Articles
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
